SINOPHARM Aktie

 

Das Instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY wird ex Dividende/Zinsen gehandelt am 16.06.2025 The instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY has its ex-dividend/interest day on 16.06.2025...

Das Instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY wird cum Dividende/Zinsen gehandelt am 13.06.2025 und ex Dividende/Zinsen am 16.06.2025 The instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY has its pre-dividend/interest day on 13.06.2025 and its ex-dividend/interest day on 16.06.2025...

SINGAPORE, May 20, 2025 /PRNewswire/ -- MediThinQ, the South Korean company specialising in wearable extended reality (XR) surgical displays, announced a strategic partnership with Sinopharm, a state-owned Chinese healthcare giant and the largest pharmaceutical and medical distribution......

SINOPHARM (01099.HK)'s 2024 revenue fell 2% YoY, while net profit dropped 22.1% YoY, both of which missed market consensus, Huatai Securities issued a research report saying.Looking ahead to 2025, Huatai Securities was optimistic about positive net profit growth of the Group, and kept rating at Buy, with its target price tri......

SINOPHARM (01099.HK)'s FY2024 revenue was broadly in line with market consensus, but earnings missed forecasts, mainly due to margin pressure and an one-off impairment of goodwill and intangible assets at Guoda Pharmacy, CLSA released a research report saying.The broker dropped its target price for SINOPHARM from $24.8 to $2......

SINOPHARM (01099.HK) announced its full-year results for the period ending December, 2024. Revenue reached RMB584.508 billion, down 2% YoY. It recorded a net profit of RMB7.05 billion, marking a 22.1% YoY decline. EPS stood at RMB2.26. The company declared a final DPS of RMB0.68, compared to RMB0.87 in the same period of the pre......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

UOB Kay Hian issued a research report believing that SINOPHARM (01099.HK)'s 9M24 results were poor, with both revenue and earnings missing expectations. Although the low interest rate environment will help the Company reduce its financial costs, policy uncertainties and weak economy may continue to affect the Company's e......

SINOPHARM (01099.HK)'s 3Q24 revenue rose modestly by 1.9% YoY to RMB147.7 billion , while net profit fell 20.9% YoY to RMB1.575 billion, mainly due to a decline in gross profit margin, CLSA issued a research report saying. However, the broker still believed that the improved macro environment and the recent management change......

Morgan Stanley released a research report lowering its 2024-2030 earnings forecasts by 4-10% due to lower revenue and gross margins after SINOPHARM (01099.HK) announced its 3Q24 results. The broker also cut its target price and scenario values by 4-9%.Morgan Stanley cut its target price for SINOPHARM from $25 to $24, which is eq......

SINOPHARM (01099.HK) announced its results for 1-3Q ended September. According to Chinese accounting standards, its revenue reached RMB442.423 billion, down 0.8% YoY, while its net profit amounted to RMB5.279 billion, down 13.4% YoY. Its EPS stood at RMB1.69.~AAStocks Financial NewsWeb Site: www.aastocks.com...

SINOPHARM (01099.HK) announced its results for the first three quarters ended September 2024, prepared in accordance with the PRC GAAP, with a turnover of RMB442.423 billion, down 0.8% YoY. Net profit amounted to RMB5.279 billion, down 13.4% YoY, with an EPS of RMB1.69.~AAStocks Financial NewsWeb Site: www.aastocks.com...

TRAD CHI MED (00570.HK) announced that the preconditions for Sinopharm Common Wealth's proposal to privatize the company at $4.6 per share have not been met. As a result, the proposal lapsed on October 18, and the company's listing status on the Hong Kong Stock Exchange will not be withdrawn.Opening 14.92% lower at $3.25......

CICC wrote in a report that SINOPHARM (01099.HK)'s 1H24 operating revenue was RMB294.727 billion, down 2.07% YoY. Net profit attributable to the parent was RMB3.704 billion, falling 9.76% YoY, with a corresponding EPS of RMB1.19, in line with expectations.According to the broker, SINOPHARM's distribution business continu......

In a recent report, Morgan Stanley lowered its profit forecast for 2024-2030 on SINOPHARM (01099.HK) by 3-9% due to lower revenue and gross margins, after the company announced its 1H24 results.The broker lowered its target price and scenario value for SINOPHARM by 7-8% and dropped its target price from $27 to $25, equivalent to......

Citi Research wrote in a report that SINOPHARM (01099.HK) management said in the 1H24 results conference call that revenue has begun to recover in July, with YoY growth recorded. The recovery is expected to continue in 2H24, with 2H gross profit margin improving HoH. The company's financial expense ratio fell by 11 bps to 0.......

SINOPHARM (01099.HK) opened flat today (26 Aug) and soon retreated. It is now trading at $17.36, slumping 6.47%, with 473,200 shares traded, involving a capital of $8.5088 million.SINOPHARM's 1H24 profit fell 9.8% YoY to RMB3.704 billion, while revenue dropped 2.1% to RMB294.727 billion, mainly due to the decline in revenue ......

SINOPHARM (01099.HK) announced its interim results for the six months ended June this year, with revenue of RMB294.727 billion, down 2.1% YoY. Net profit declined 9.8% YoY to RMB3.704 billion, with an EPS of RMB1.19. No dividend was declared.During the period, the pharmaceutical distribution business remained relatively stable, ......

~AAStocks Financial NewsWeb Site: www.aastocks.com...

Sinopharm unit denies link to firm suspected of illegally purchasing cadavers...